PubMed:10992168 JSONTXT

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":126,"end":138},"obj":"HP_0100602"},{"id":"T2","span":{"begin":465,"end":477},"obj":"HP_0100602"},{"id":"T3","span":{"begin":1131,"end":1143},"obj":"HP_0100602"},{"id":"T4","span":{"begin":1212,"end":1224},"obj":"HP_0100602"}],"text":"Preeclampsia prevention: lessons from the low-dose aspirin therapy trials.\nThe ability of low-dose aspirin therapy to prevent preeclampsia is controversial. The 19 randomized, placebo-controlled trials of low-dose aspirin therapy reported in the literature were categorized according to the risk factors of the women studied-nulliparity, underlying medical illness, poor obstetric history, and multiple gestation. Low-dose aspirin therapy reduced the incidences of preeclampsia among women with poor obstetric histories and among high-risk nulliparous women but was ineffective among women with underlying medical illness. It was marginally effective among low-risk nulliparous women, and benefits for women with multiple gestations are unclear. More research is needed to better identify high-risk nulliparous women who might benefit from the use of low-dose aspirin therapy and to define potential benefits for women with multiple gestations. The differential effects of low-dose aspirin therapy in the various risk groups are probably a result of varying roles in the groups of abnormal arachidonic acid metabolism in mediating preeclampsia. It is premature to abandon the use of low-dose aspirin therapy for preeclampsia prevention."}

{"project":"Preeclampsia","denotations":[{"id":"PD-Preeclampsia-B_T1","span":{"begin":0,"end":12},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T2","span":{"begin":126,"end":138},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T3","span":{"begin":465,"end":477},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T4","span":{"begin":1131,"end":1143},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T5","span":{"begin":1212,"end":1224},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"Preeclampsia prevention: lessons from the low-dose aspirin therapy trials.\nThe ability of low-dose aspirin therapy to prevent preeclampsia is controversial. The 19 randomized, placebo-controlled trials of low-dose aspirin therapy reported in the literature were categorized according to the risk factors of the women studied-nulliparity, underlying medical illness, poor obstetric history, and multiple gestation. Low-dose aspirin therapy reduced the incidences of preeclampsia among women with poor obstetric histories and among high-risk nulliparous women but was ineffective among women with underlying medical illness. It was marginally effective among low-risk nulliparous women, and benefits for women with multiple gestations are unclear. More research is needed to better identify high-risk nulliparous women who might benefit from the use of low-dose aspirin therapy and to define potential benefits for women with multiple gestations. The differential effects of low-dose aspirin therapy in the various risk groups are probably a result of varying roles in the groups of abnormal arachidonic acid metabolism in mediating preeclampsia. It is premature to abandon the use of low-dose aspirin therapy for preeclampsia prevention."}

{"project":"Preeclampsia-compare","denotations":[{"id":"PD-Preeclampsia-B_T1","span":{"begin":0,"end":12},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T2","span":{"begin":126,"end":138},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T3","span":{"begin":465,"end":477},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T4","span":{"begin":1131,"end":1143},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T5","span":{"begin":1212,"end":1224},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"Preeclampsia prevention: lessons from the low-dose aspirin therapy trials.\nThe ability of low-dose aspirin therapy to prevent preeclampsia is controversial. The 19 randomized, placebo-controlled trials of low-dose aspirin therapy reported in the literature were categorized according to the risk factors of the women studied-nulliparity, underlying medical illness, poor obstetric history, and multiple gestation. Low-dose aspirin therapy reduced the incidences of preeclampsia among women with poor obstetric histories and among high-risk nulliparous women but was ineffective among women with underlying medical illness. It was marginally effective among low-risk nulliparous women, and benefits for women with multiple gestations are unclear. More research is needed to better identify high-risk nulliparous women who might benefit from the use of low-dose aspirin therapy and to define potential benefits for women with multiple gestations. The differential effects of low-dose aspirin therapy in the various risk groups are probably a result of varying roles in the groups of abnormal arachidonic acid metabolism in mediating preeclampsia. It is premature to abandon the use of low-dose aspirin therapy for preeclampsia prevention."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":74},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":75,"end":156},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":157,"end":413},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":414,"end":622},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":623,"end":745},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":746,"end":944},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":945,"end":1144},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":1145,"end":1236},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":74},"obj":"Sentence"},{"id":"T2","span":{"begin":75,"end":156},"obj":"Sentence"},{"id":"T3","span":{"begin":157,"end":413},"obj":"Sentence"},{"id":"T4","span":{"begin":414,"end":622},"obj":"Sentence"},{"id":"T5","span":{"begin":623,"end":745},"obj":"Sentence"},{"id":"T6","span":{"begin":746,"end":944},"obj":"Sentence"},{"id":"T7","span":{"begin":945,"end":1144},"obj":"Sentence"},{"id":"T8","span":{"begin":1145,"end":1236},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Preeclampsia prevention: lessons from the low-dose aspirin therapy trials.\nThe ability of low-dose aspirin therapy to prevent preeclampsia is controversial. The 19 randomized, placebo-controlled trials of low-dose aspirin therapy reported in the literature were categorized according to the risk factors of the women studied-nulliparity, underlying medical illness, poor obstetric history, and multiple gestation. Low-dose aspirin therapy reduced the incidences of preeclampsia among women with poor obstetric histories and among high-risk nulliparous women but was ineffective among women with underlying medical illness. It was marginally effective among low-risk nulliparous women, and benefits for women with multiple gestations are unclear. More research is needed to better identify high-risk nulliparous women who might benefit from the use of low-dose aspirin therapy and to define potential benefits for women with multiple gestations. The differential effects of low-dose aspirin therapy in the various risk groups are probably a result of varying roles in the groups of abnormal arachidonic acid metabolism in mediating preeclampsia. It is premature to abandon the use of low-dose aspirin therapy for preeclampsia prevention."}